Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics

Abeona Therapeutics Inc. (ABEO)

Today's Latest Price: $1.65 USD

0.24 (17.02%)

Updated Nov 27 1:00pm

Add ABEO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABEO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ABEO is -0.02 -- better than only 6.6% of US stocks.
  • ABEO's went public 34.25 years ago, making it older than 92.52% of listed US stocks we're tracking.
  • Revenue growth over the past 12 months for Abeona Therapeutics Inc comes in at -139.84%, a number that bests merely 0.35% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ABEO, based on their financial statements, market capitalization, and price volatility, are HTBX, CRIS, ALBO, ADRO, and VTVT.
  • ABEO's SEC filings can be seen here. And to visit Abeona Therapeutics Inc's official web site, go to www.abeonatherapeutics.com.

ABEO Stock Price Chart Interactive Chart >

Price chart for ABEO

ABEO Price/Volume Stats

Current price $1.65 52-week high $5.19
Prev. close $1.41 52-week low $0.99
Day low $1.46 Volume 5,202,500
Day high $1.75 Avg. volume 1,527,525
50-day MA $1.31 Dividend yield N/A
200-day MA $2.36 Market Cap 162.57M

Abeona Therapeutics Inc. (ABEO) Company Bio

Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.

ABEO Latest News Stream

Event/Time News Detail
Loading, please wait...

ABEO Latest Social Stream

Loading social stream, please wait...

View Full ABEO Social Stream

Latest ABEO News From Around the Web

Below are the latest news stories about Abeona Therapeutics Inc that investors may wish to consider to help them evaluate ABEO as an investment opportunity.

Abeona Therapeutics rallies on B.Riley's Buy rating

B.Riley initiated Abeona Therapeutics ([[ABEO]] +12.2%) with a Buy rating, PT $5 indicating a more than double upside from current levels.Analyst Justin Zelin believes that the company is now positioned to potentially have three rare disease approvals by 2023.Quick look at its robust pipeline:Led by balance sheet concerns, management turnover,...

Seeking Alpha | September 18, 2020

Abeona Therapeutics (ABEO) Investor Presentation - Slideshow

The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates

Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS…

GlobeNewswire | August 10, 2020

Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting

EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands.

Yahoo | July 10, 2020

Abeona Restarts Enrollment in Connective Tissue Disorder Study

Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

Yahoo | July 9, 2020

Read More 'ABEO' Stories Here

ABEO Price Returns

1-mo 54.21%
3-mo -29.79%
6-mo -46.08%
1-year -51.04%
3-year -90.46%
5-year -63.09%
YTD -49.54%
2019 -54.20%
2018 -54.95%
2017 226.80%
2016 44.35%
2015 -2.61%

Continue Researching ABEO

Want to see what other sources are saying about Abeona Therapeutics Inc's financials and stock price? Try the links below:

Abeona Therapeutics Inc (ABEO) Stock Price | Nasdaq
Abeona Therapeutics Inc (ABEO) Stock Quote, History and News - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7852 seconds.